E2 Raises $80M in Series C Funding to Advance Pulmonary Embolism Treatment

Why It Matters

The infusion of $80 million fast‑tracks a more efficient, potentially life‑saving PE treatment, positioning E2 to reshape the VTE market and lower hospital costs.

Key Takeaways

• $80M Series C led by Gilde, Norwest.
• Hēlo platform enables single-pass pulmonary embolism removal.
• Dual-action catheter combines aspiration and mechanical disruption.
• Funding fuels North American and global commercial expansion.
• Board adds investors with proven VTE scaling experience.

Pulse Analysis

Pulmonary embolism remains the third leading cause of cardiovascular death, yet conventional therapies—systemic thrombolysis and open surgery—often fall short due to delayed action, bleeding risk, or procedural complexity. Over the past decade, mechanical thrombectomy has emerged as a viable alternative, driven by advances in catheter design and growing clinical evidence that rapid clot extraction improves survival and reduces long‑term complications. Hospitals are increasingly seeking devices that can deliver decisive outcomes while fitting into existing interventional workflows.

E2’s Hēlo® platform distinguishes itself with a patented dual‑action mechanism that merges aspiration and mechanical disruption within a low‑profile catheter. This architecture allows physicians to achieve single‑pass clot removal, cutting procedure time and anesthesia exposure compared with multi‑pass systems. By integrating aspiration, contrast injection, and fluid infusion into one device, the platform simplifies training and reduces inventory complexity, offering a clear operational advantage over incremental upgrades from established players such as Stryker and Boston Scientific.

The $80 million Series C injection signals strong investor confidence in both the technology and the expanding VTE market. Gilde Healthcare and Norwest bring not only capital but also strategic guidance that can accelerate regulatory clearance and hospital adoption across North America and Europe. If E2’s rollout succeeds, hospitals could see lower procedural costs, higher throughput, and improved patient outcomes, potentially establishing Hēlo as a new standard of care for pulmonary embolism and influencing future device innovation in the broader endovascular space.

Deal Summary

E2, a commercial-stage medical technology firm, closed an $80 million Series C round led by Gilde Healthcare and Norwest, with participation from existing investors Santé Ventures, 415 Capital, S3 Ventures, Panakès Partners and M&L Healthcare Investments. The funding will accelerate commercialization of its Hēlo® Thrombectomy Platform for pulmonary embolism treatment. The round underscores strong investor confidence in E2’s innovative VTE solution.